Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NePathe

- PMLiVE

Eisai wins US approval for chemotherapy side effects drug

FDA backs Akynzeo to treat nausea and vomiting

- PMLiVE

Amgen leukaemia drug gets FDA priority review

Adds to breakthrough status for blinatumomab

Bristol Myers Squibb logo

BMS drops US application for ‘breakthrough’ hep C combination

Blames the 'rapidly evolving' market for asunaprevir withdrawal

Teva Pharma logo

Teva scales back R&D as Copaxone competition looms

Copaxone accounts for almost 40% of its revenue

Medical device firms told to address cybersecurity risks

FDA says online security should be part of a device's design and development

- PMLiVE

FDA awards $19m in rare disease grants

US regulator supports 15 orphan drug projects

- PMLiVE

Humira gets FDA nod for paediatric Crohn’s disease

Can be used as treatment for patients as young as six

- PMLiVE

Celgene’s Otezla gains new US psoriasis approval

FDA backs oral drug in moderate to severe plaque psoriasis

- PMLiVE

FDA approves Lilly’s GLP-1 diabetes drug Trulicity

The once-weekly treatment is set to compete with Bydureon, Tanzeum and Victoza

- PMLiVE

FDA approves AZ’s opioid-induced constipation drug Movantik

Trials showed positive reactions to the treatment

- PMLiVE

FDA panel backs Novo Nordisk’s liraglutide for obesity

Committee says diabetes drug could be used to reduce weight

- PMLiVE

Pre-chemotherapy indication for Xtandi in prostate cancer

Astellas drug set to compete with J&J’s Zytiga

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links